Vaccinating children for the SARS-CoV-2 virus surely isn’t a move that pleases everyone. Those who are skeptical may have a new reason to be likewise. COVID vaccination with Pfizer’s jab for children of 2,3, and 4 years of age, meaning the two-dose regimen, didn’t trigger a sufficient immune response.
The news comes from Pfizer and BioNTech themselves, according to Yahoo! News. Although there was no use for safety concerns, according to Pfizer and BioNTech, a new clinical trial is on its way. However, those children of six months to two years of age have shown enough immune response due to the vaccination.
Participants were given one-tenth of the dose that adults received, meaning that the little ones received only 3 micrograms.
The booster vaccine dose will be given after two months
The same publication mentioned above tells us that the companies in charge said that those children of 2 to 4 years of age would also receive a third vaccine dose (aka booster doses) two months after they were given the second dose.
Jerica Pitts, a spokeswoman of Pfizer, declared for the New York Times:
The goal here is to understand the potential of protection of the third dose.
Pitts also explained that the dosage won’t be increased, although the goal is to see how three doses will work.
The expectation is for the third dose to provide enough protection, particularly for the new Omicron variant. That’s what Kawsar Talaat claims, who’s one of the principal investigators of Pfizer’s pediatric trial. He declared, as cited by The New York Times:
I think that a third dose will give a nice boost, and honestly, this is really exciting — as we know from the adult data, three doses is probably better for omicron. And I think it’ll be good to have similar data for children.
The new Omicron variant was first found in South Africa, and it triggered a lot of concerns in the medical world.